{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:09:50Z","timestamp":1768478990599,"version":"3.49.0"},"reference-count":67,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Posaconazole has become an important part of the antifungal armamentarium in the prophylaxis and salvage treatment of invasive fungal infections (IFIs). Structurally related to itraconazole, posaconazole displays low oral bioavailability due to poor solubility, with significant drug interactions and gastrointestinal disease also contributing to the generally low posaconazole plasma concentrations observed in patients. While therapeutic drug monitoring (TDM) of plasma concentrations is widely accepted for other triazole antifungal agents such as voriconazole, the utility of TDM for posaconazole is controversial due to debate over the relationship between posaconazole exposure in plasma and clinical response to therapy. This review examines the available evidence for a relationship between plasma concentration and clinical efficacy for posaconazole, as well as evaluating the utility of TDM and providing provisional target concentrations for posaconazole therapy. Increasing evidence supports an exposure-response relationship for plasma posaconazole concentrations for prophylaxis and treatment of IFIs; a clear relationship has not been identified between posaconazole concentration and toxicity. Intracellular and intrapulmonary concentrations have been studied for posaconazole but have not been correlated to clinical outcomes. In view of the high mortality and cost associated with the treatment of IFIs, increasing evidence of an exposure-response relationship for posaconazole efficacy in the prevention and treatment of IFIs, and the common finding of low posaconazole concentrations in patients, TDM for posaconazole is likely to be of significant clinical utility. In patients with subtherapeutic posaconazole concentrations, increased dose frequency, administration with high-fat meals, and withdrawal of interacting medications from therapy are useful strategies to improve systemic absorption.<\/jats:p>","DOI":"10.1128\/aac.05900-11","type":"journal-article","created":{"date-parts":[[2012,3,6]],"date-time":"2012-03-06T05:49:51Z","timestamp":1331012991000},"page":"2806-2813","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":125,"title":["Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring"],"prefix":"10.1128","volume":"56","author":[{"given":"Michael J.","family":"Dolton","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, University of Sydney, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John E.","family":"Ray","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology &amp; Toxicology, SydPath, St. Vincent's Hospital, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Marriott","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Clinical Infectious Diseases, St. Vincent's Hospital, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"McLachlan","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Sydney, Sydney, Australia"},{"name":"Centre For Education and Research on Ageing, Concord Repatriation General Hospital, Sydney, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.1.137-142.2004"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00705-08"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.11.021"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00637-11"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/519937"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2007.01.021"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01396-09"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00663-08"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061094"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.261"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.2788-2795.2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004271402"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01977.x"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"de Pauw B","year":"2008","unstructured":"de PauwB. 2008. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group. Clin. Infect. Dis. 46:1813\u20131821.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01178-08"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-011-1288-9"},{"key":"e_1_3_2_18_2","unstructured":"European Medicines Agency. 2010. European Public Assessment Reports summary for the public: Noxafil (posaconazole). European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000610\/human_med_000937.jsp&murl=menus\/medicines\/medicines.jsp&mid=WC0b01ac058001d125."},{"key":"e_1_3_2_19_2","unstructured":"European Medicines Agency. 2005. Noxafil: EPAR\u2014scientific discussion. European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/human\/000610\/WC500037781.pdf."},{"key":"e_1_3_2_20_2","unstructured":"European Medicines Agency. 2011. Noxafil. EPAR annex 1. Summary of product characteristics. European Medicines Agency London United Kingdom. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000610\/WC500037784.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544020-00006"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01407-09"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/657306"},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal A","year":"2004","unstructured":"GhosalA. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. 32:267\u2013271.","journal-title":"Drug Metab. Dispos."},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm389"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2009.06.030"},{"key":"e_1_3_2_27_2","first-page":"385","volume-title":"Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother.","author":"Groll AH","year":"2000","unstructured":"GrollAH. 2000. Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., Toronto, Canada, p 385. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00157-06"},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1399-0012.2003.00060.x","article-title":"Gastroesophageal reflux disease in lung transplant recipients","volume":"17","author":"Hadjiliadis D","year":"2003","unstructured":"HadjiliadisD. 2003. Gastroesophageal reflux disease in lung transplant recipients. Clin. Transplant. 17:363\u2013368.","journal-title":"Clin. Transplant."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00062-11"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir023"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.64"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00213-09"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01027-09"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.28.10.1223"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00889-09"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1592\/phco.27.12.1627"},{"key":"e_1_3_2_38_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.","author":"Krishna G","year":"2011","unstructured":"KrishnaG MartinhoMLM O'MaraE. 2011. Improved bioavailability of posaconazole (POS) new tablets and capsule formulations relative to oral suspension. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr A2-573 American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_39_2","volume-title":"Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother.","author":"Krishna G","year":"2011","unstructured":"KrishnaG MartinhoMLM PrestonRA O'MaraE. 2011. Posaconazole (POS) multiple dose pharmacokinetics (PK) and safety in healthy volunteers from a new solid oral tablet formulation. Abstr. 51st Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL, abstr A2-573. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01034-08"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men","volume":"23","author":"Krishna G","year":"2007","unstructured":"KrishnaG ParsonsA KantesariaB MantT. 2007. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr. Med. Res. Opin. 23:545\u2013552.","journal-title":"Curr. Med. Res. Opin."},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X187937"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00939-09"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.2165\/11319340-000000000-00000"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01671-10"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1086\/318483"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2010.03680.x"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00931-09"},{"key":"e_1_3_2_49_2","unstructured":"Merck & Co. 2010. Noxafil US Prescribing Information revised September 2010. Merck & Co Whitehouse Station NJ. http:\/\/www.spfiles.com\/pinoxafil.pdf."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2710.2009.01055.x","article-title":"Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers","volume":"34","author":"Moton A","year":"2009","unstructured":"MotonA KrishnaG WangZ. 2009. Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. J. Clin. Pharm. Ther. 34:301\u2013311.","journal-title":"J. Clin. Pharm. Ther."},{"key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1439-0507.2006.01297.x","article-title":"HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases","volume":"49","author":"M\u00fcller C","year":"2006","unstructured":"M\u00fcllerC ArndtM QueckenbergC CornelyOA TheisohnM. 2006. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 49(Suppl. 1):17\u201322.","journal-title":"Mycoses"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1086\/523576"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00150-10"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1086\/504490"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","article-title":"Posaconazole plasma concentrations in critically ill patients","volume":"33","author":"Ray J","year":"2011","unstructured":"RayJ CampbellL RudhamS NguyenQ MarriottD. 2011. Posaconazole plasma concentrations in critically ill patients. Ther. Drug Monit. 33:387\u2013392.","journal-title":"Ther. Drug Monit."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00163-06"},{"key":"e_1_3_2_57_2","unstructured":"Schering-Plough. 2011. Pharmacokinetics safety and tolerability of intravenous posaconazole solution followed by oral posaconazole suspension in subjects at high risk for invasive fungal infections (study P05520AM1). NLM identifier NCT01075984. U.S. National Library of Medicine Bethesda MD. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01075984."},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2006.06.011"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01325-10"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2011.07.013","article-title":"Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review","volume":"39","author":"Sinnollareddy M","year":"2012","unstructured":"SinnollareddyM PeakeSL RobertsMS LipmanJ RobertsJA. 2012. Using pharmacokinetics and pharmacodynamics to optimise dosing of antifungal agents in critically ill patients: a systematic review. Int. J. Antimicrob. Agents 39:1\u201310.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00240-09"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70297-8"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.2.658-666.2006"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061098"},{"key":"e_1_3_2_65_2","unstructured":"U.S. Food and Drug Administration. 2008. Noxafil (posaconazole) oral suspension. U.S. Food and Drug Administration Silver Spring MD. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2006\/022027_noxafil_toc.cfm."},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.2165\/11592630-000000000-00000"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1086\/508774"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2002.51108.x"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05900-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05900-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:20:43Z","timestamp":1645482043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05900-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.1128\/AAC.05900-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05900-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"2012-05-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}